This inventor holds 1 USPTO granted patent and 3 published patent applications and 3 EPO patents. Top assignees: Tessa Therapeutics Pte. Ltd, The University of North Carolina at Chapel Hill. Active years: 2026.
Company Filing History:
1 out of 3 
1 out of 1,325 
Years Active: 2026
Title: Barbara Savoldo - Innovator in Cancer Treatment
Introduction
Barbara Savoldo is a prominent inventor based in Chapel Hill, NC (US). She is affiliated with Baylor College of Medicine, where she contributes to groundbreaking research in cancer treatment. Despite having no granted patents, her work in the field of modified natural killer T-cells (NKTs) showcases her innovative approach to therapeutic methods.
Latest Patent Applications
Barbara Savoldo has been involved in several significant patent applications. One of her latest applications is titled "Natural Killer T-Cells and Methods of Using the Same." This application discloses modified NKTs expressing human IL-12, along with compositions and therapeutic methods for utilizing these modified NKTs. The NKTs described are reprogrammed to demonstrate long-term persistence, particularly when IL-12 expression is coupled with a chimeric antigen receptor (CAR). This innovation aims to enhance the capacity of NKTs to eliminate tumor cells effectively.
Another notable application is "Treatment of CD30-Positive Cancer." This application outlines methods for treating CD30-positive cancer in subjects, which involve administering lymphodepleting chemotherapy alongside CD30-specific CAR-expressing cells. These applications reflect her commitment to advancing cancer therapies through innovative cellular modifications.
Conclusion
Barbara Savoldo's contributions to the field of cancer treatment through her innovative research and patent applications highlight her role as a significant inventor. Her work continues to pave the way for new therapeutic methods that could transform cancer care.